SURABAYA | JATIMSATUNEWS.COM: The keyword “WuXi” has appeared among Google’s trending topics in Indonesia today (November 11).
This follows widespread news coverage regarding the U.S. government (the Pentagon) officially removing the Chinese biotechnology giant, WuXi AppTec, from its military-linked blacklist.
Extensive reporting by various national media outlets in Indonesia has prompted many people to search for information about the company.
Sorotan
Behind the Surge in Searches
Removal from the U.S. Blacklist

According to a report by CNBC Indonesia, the U.S. Department of Defense (the Pentagon) has officially removed WuXi AppTec from its list of companies alleged to have ties to the Chinese military (under Section 1260H).
This announcement was made earlier this week, following an official notice in the Federal Register.
Legal Victory
The Pentagon’s decision follows a ruling by a U.S. federal court in favor of WuXi AppTec.
The pharmaceutical company had previously challenged the U.S. government, arguing that the allegations of military involvement were baseless and detrimental to its business operations.
Surge in Stock Price

News of the sanctions being lifted triggered a positive sentiment in the global stock market.
According to data from Investing, shares of WuXi AppTec on the Hong Kong Stock Exchange jumped by more than 6% at the market opening.
Read also: Strengthening International Cooperation, UISI Receives a Visit from an SVCCI China Delegation
Who is WuXi AppTec?
Chinese Biotech Giant of Pharmaceutical Industry

WuXi AppTec is a leading Chinese provider of research, development, and manufacturing services for the pharmaceutical industry.
The company serves as a key partner to many global pharmaceutical giants in the United States and Europe, including Pfizer, AstraZeneca, and GSK.
The U.S. market accounts for the largest share of their revenue; therefore, its removal from the blacklist is considered a major victory for the company’s continued business operations.***
Author: YAN


Komentar Pembaca
Belum ada komentar pada artikel ini. Jadilah yang pertama.
Minimal 10 karakter, maksimal 1000. Maksimal satu tautan. Semua komentar ditinjau redaksi sebelum tampil.